Merck uprifosbuvir news

In an SEC filing, Merck said it would record a pretax impairment charge of $2.9 billion for HCV candidate uprifosbuvir (MK-3862) based on "recent changes to the product profile, as well as changes to its expectations for pricing and the market opportunity." The pharma gained uprifosbuvir in its $3.9 billion acquisition of Idenix Pharmaceuticals Inc. in 2014.

Merck said that the impairment was not due to the safety or the efficacy of the program and that the current trials of the uridine nucleotide analog HCV NS5B polymerase inhibitor would continue...